title: Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
abstract: The effect of somatostatin on thyroid function was studied in 12 patients with growth hormone (GH)-secreting and eight patients with clinically non-functioning adenomas (NFA) and normal pituitary/ thyroid axis; the patients were subjected to the administration of octreotide (OCT), which is a long-acting somatostatin analog. All the patients received an acute test with 100 micrograms of OCT, both short term (1 month) and long term (6 months), with doses ranging from 300 to 600 micrograms/day. Serum thyroxine (T4), triiodothyronine (T3), free T4, free T3, thyroglobulin and basal and thyrotropin (TSH)-releasing hormone (TRH)-stimulated TSH were evaluated before and after 1 and 6 months of therapy. Circulating GH and insulin-like growth-factor I (IGF-I) in acromegalics and GH, IGF-I and alpha-subunit in NFA were assessed at baseline and every month. The acute administration of 100 micrograms of OCT significantly reduced the TSH response to TRH (p < 0.01) in both acromegalics and NFA. In all the patients OCT administration caused a significant decrease of GH, IGF-I and alpha-subunit levels (p < 0.01). In addition, after 1 month of therapy both baseline and TRH-induced TSH secretion were decreased significantly in acromegalics and NFA. After 6 months of therapy, baseline and TRH-induced TSH was still reduced in NFA. Conversely, in acromegalics, baseline TSH levels were increased while TSH response to TRH was inhibited. No change of T4, T3, free T4 and free T3 was observed in NFA, whereas a slight but significant increase of T4 and decrease of T3 was recorded in acromegalics.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Oncology and Endocrinology, Federico II, Naples, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: B
authors.initials: B
authors.lastname: Merola
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: P
authors.initials: P
authors.lastname: Marzullo
authors.forename: G
authors.initials: G
authors.lastname: Cerbone
authors.forename: S
authors.initials: S
authors.lastname: Longobardi
authors.forename: C
authors.initials: C
authors.lastname: Di Somma
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013997:Time Factors
chemical_list: D013973:Thyrotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I; D013972:Thyrotropin; D013006:Growth Hormone; D015282:Octreotide